Amrutanjan Health Care Limited announced on 17 April 2026 the launch of a new range of products across Personal Care, Wound Care, and Pain Management categories. The announcement was made in compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The company disclosed these developments through a detailed filing to the National Stock Exchange of India Limited and BSE Limited.

Personal Care Segment

The company marked its strategic entry into the razors category, expanding into the fast-growing grooming segment. The Personal Care portfolio includes three new products:

Developed using advanced Korean technology, the women's razor range under the Comfy brand represents an extension of the company's vision to build a comprehensive women's wellness and personal care portfolio. The men's razor range enables entry into the male grooming segment, leveraging brand trust to unlock new growth avenues.

Wound Care Portfolio

Amrutanjan introduced Amrutanjan Plastry, a range of medicated antiseptic plasters leveraging the company's trusted equity in pain relief and care. The product range includes Regular and Wash proof variants offered in a convenient jar format. Key product features include breathable fabric, strong adhesion, and protection against bacteria and water. The jar contains 100 Regular and 70 Washproof variants, designed for ease of use and storage.

Pain Management Expansion

The company launched Amrutanjan Ortho Pain Relief + Oil, a significant addition to its pain management portfolio. The product features an advanced heat therapy formulation enriched with Gandhapura and Capsaicin. According to clinical evidence, the oil provides up to 66% pain reduction in 8 weeks of usage. The product is designed for targeted relief from back, shoulder, joint, and muscular pain along with stiffness. The packaging includes a 20% extra volume offering and is positioned as a 100% Ayurvedic solution for Osteoarthritis and Rheumatoid Arthritis.

Product Launch Summary

The launches represent the company's strategy to strengthen its portfolio through relevant and high-utility categories while expanding presence in high-growth segments.

Amrutanjan Health Care Limited has announced the rephrasing of the Second Phase ESOP 2 of its existing Employee Stock Option Scheme 2020. The company communicated this development to stock exchanges on April 17, 2026, in compliance with regulatory requirements.

Committee Approval and Regulatory Compliance

The rephrasing decision received approval from the company's Nomination and Remuneration Committee/Compensation Committee through a resolution passed on April 17, 2026. The announcement was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, along with applicable circulars issued by SEBI.

ESOP Scheme Details

Corporate Communication

The formal intimation was signed by Gagan Preet Singh, General Manager - Legal, Company Secretary & Compliance Officer, and submitted to both the National Stock Exchange of India Limited and BSE Limited. The company has requested the exchanges to take the information on record and acknowledge receipt.

Company Background

Amrutanjan Health Care Limited, established in 1893, operates from its registered office at Luz Church Road, Mylapore, Chennai. The company trades on NSE under the symbol AMRUTANJAN and on BSE with scrip code 590006, with ISIN INE098F01031.